Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Татьяна Михайловна Букатина
Observed names:
T. M. Bukatina,
T. V. Bukatina,
Букатина Т. М.,
Букатина Т.М.,
Т М Букатина,
Т. М. Букатина
show all 6
Institution:
Federal State Budgetary Institution ‘Scientific Centre for Expert Evaluation of Medicinal Products’ of the Ministry of Health of the Russian Federation (SCEEMP)
Observed institutions:
Volgograd State Medical University,
Ministry of Health of the Russian Federation,
Federal State Budgetary Institution ‘Scientific Centre for Expert Evaluation of Medicinal Products’ of the Ministry of Health of the Russian Federation (SCEEMP)
ORCID:
0000-0002-7597-2926
Observed ORCID:
0000-0002-7597-2926
OpenAlex ID:
A5027329850
Immune Response Checkpoint Inhibitors: New Risks of a New Class of Antitumor Agents
2020
·
E. V. Shubnikova
, T. M. Bukatina
, et al.
·
Safety and Risk of Pharmacotherapy
·
31
PDF
Comparative Analysis of International Databases of Adverse Drug Reactions
2020
·
A. S. Kazakov
, M. A. Darmostukova
, et al.
·
Safety and Risk of Pharmacotherapy
·
12
PDF
Nonsteroidal anti-inflammatory drugs: problems of safe use
2018
·
N. Yu. Velts
, E. O. Zhuravleva
, et al.
·
Safety and Risk of Pharmacotherapy
·
12
Nanoscale Therapeutic System: Safety Assessment Features
2019
·
E. M. Bovina
, B. K. Romanov
, et al.
·
Safety and Risk of Pharmacotherapy
·
8
PDF
Post-marketing Drug Safety Research: Analysis of Recommendations of Foreign Regulators
2018
·
E. V. Shubnikova
, T. M. Bukatina
, et al.
·
Safety and Risk of Pharmacotherapy
·
8
In Vitro Method of Studying the Angiotensin Activity of Chemical Compounds
2014
·
A. A. Spasov
, D. S. Yakovlev
, et al.
·
Bulletin of Experimental Biology and Medicine
·
7
The Adverse Drug Reactions Registered During the Postmarketing Period
2019
·
E. V. Shubnikova
, M. A. Darmostukova
, et al.
·
Safety and Risk of Pharmacotherapy
·
6
Critical Overview of the Contents of Risk Management Plans for Medicines
2022
·
T. M. Bukatina
, E. V. Shubnikova
·
Safety and Risk of Pharmacotherapy
·
5
PDF
On the Issue of Safety of Non-steroidal Anti-inflammatory Drugs
2018
·
N. Yu. Velts
, T. M. Bukatina
, et al.
·
Safety and Risk of Pharmacotherapy
·
4
PDF
Правила надлежащей лабораторной практики: анализ изменений законодательства
2017
·
Н. Ю. Вельц
, Т. М. Букатина
, et al.
·
DOAJ (DOAJ: Directory of Open Access Journals)
·
4
Практические рекомендации по поиску информации о безопасности лекарственных средств
2016
·
Е. Ю. Пастернак
, Т. М. Букатина
, et al.
·
DOAJ (DOAJ: Directory of Open Access Journals)
·
4
Risk Management Plan: An Expert Analysis of Changes to the EAEU Good Pharmacovigilance Practice Requirements for the Content and Submission of the Document
2023
·
T. M. Bukatina
, E. V. Shubnikova
·
Safety and Risk of Pharmacotherapy
·
3
PDF
Современные риски лекарственных взаимодействий при применении лоперамида
2017
·
Александр Сергеевич Казаков
, Ренад Николаевич Аляутдин
, et al.
·
Экспериментальная и клиническая фармакология
·
3
Ингибиторы натрий-глюкозного котранспортера 2: риск кетоацидоза
2016
·
Т. М. Букатина
, А. С. Казаков
, et al.
·
DOAJ (DOAJ: Directory of Open Access Journals)
·
3
Система управления рисками - важная часть правил надлежащей практики фармаконадзора (GVP)
2016
·
А. С. Казаков
, К. Э. Затолочина
, et al.
·
DOAJ (DOAJ: Directory of Open Access Journals)
·
3
Post-marketing pharmacovigilance methods: Spontaneous reports and scientifi c literature monitoring (review)
2026
·
T. M. Bukatina
·
Safety and Risk of Pharmacotherapy
·
2
PDF
Risk Management Plan: Expert Review of Applications for Marketing Authorisation in the EAEU Depending on the Type of Medicinal Product (Review)
2024
·
T. M. Bukatina
, E. V. Shubnikova
·
Safety and Risk of Pharmacotherapy
·
2
PDF
Ivermectin: Evaluation of Efficacy and Safety in COVID-19
2022
·
E. V. Shubnikova
, N. A. Susekova
, et al.
·
Safety and Risk of Pharmacotherapy
·
2
PDF
Правила надлежащей лабораторной практики
2016
·
Н. Ю. Вельц
, Р. Н. Аляутдин
, et al.
·
DOAJ (DOAJ: Directory of Open Access Journals)
·
2
Antithrombotic Activity of a New P2Y1 Receptor Antagonist, Substance Sbt-119, on Experimental Models of Thromboses in Rats
2014
·
D. S. Yakovlev
, A. A. Spasov
, et al.
·
Bulletin of Experimental Biology and Medicine
·
2
Risk Assessment Algorithms in Pharmacovigilance: A Review
2025
·
T. M. Bukatina
·
Safety and Risk of Pharmacotherapy
·
1
Bempedoic Acid: Safety and Efficiacy of a New Lipid-Lowering Agent
2023
·
I. A. Mazerkina
, T. V. Bukatina
, et al.
·
Safety and Risk of Pharmacotherapy
·
1
PDF
Safety of Antibacterial and Antiprotozoal Medicinal Products
2022
·
E. V. Shubnikova
, T. M. Bukatina
, et al.
·
Safety and Risk of Pharmacotherapy
·
1
PDF
Drug Safety Monitoring—International Information
2020
·
E. V. Shubnikova
, T. M. Bukatina
, et al.
·
Safety and Risk of Pharmacotherapy
·
1
PDF
Myopathy Caused by the Interaction of Colchicine and Statins
2018
·
A. S. Kazakov
, M. A. Darmostukova
, et al.
·
Safety and Risk of Pharmacotherapy
·
1
PDF
Show more works
View as search
Works count:
57
Citation count:
134
H-index:
6
I10-index:
3
Year
Topic
Type